



To,
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex, Bandra (East),
Mumbai 400 051.

Date: 10th November, 2025

NSE Symbol – NIDAN

Dear Sir/Madam,

Subject : Outcome of the Board Meeting of Nidan Laboratories and Healthcare Limited held on Monday, 10th November, 2025.

This is to inform you that pursuant to Regulation 30 & Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") and other applicable provisions, the Board of Directors of the Company at its meeting held today have:

1. Approved the Unaudited Financial Results of the Company for the half year ended 30th September, 2025;
2. Taken on record the Limited review Report by the Statutory Auditors of the Company for the aforesaid results;

In view of the above, we hereby enclose the following:

1. Unaudited Financial Results of the Company for the half year ended 30th September, 2025.
2. Limited Review Report on unaudited Financial Results of the Company for the half year ended 30th September, 2025.

The extract of Unaudited Financial Results shall be published in the newspapers in the format prescribed under Regulation 47 of the (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The meeting of the Board of Directors of the Company commenced at 11.30 AM and concluded at 02:45 PM.

This is for your information and records.

Thanking you,

Yours sincerely,

For Nidan Laboratories and Healthcare Limited

Tejal Anil Jayakar
Executive Director & CFO
(DIN: 07984686)





R. K. CHAPAWAT & CO.

CHARTERED ACCOUNTANTS

Limited Review Report on unaudited financial results of Nidan Laboratories & Healthcare Limited for the half year ended 30 September 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of Nidan Laboratories & Healthcare Limited

1. We have reviewed the accompanying Statement of unaudited financial results of **Nidan Laboratories & Healthcare Limited** ("the Company") for the Half Year ended 30th September 2025 being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 ("Listing Regulations").

2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting, prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For R.K Chapawat & Co.
Chartered Accountants
Firm's Registration No. 101708W


Kamlesh Chapawat
Partner

M. No. 181441

UDIN: - 25181441BMNTNA7121

Place: Mumbai

Date: 10th November 2025



<p style="text-align: center;">Nidan Laboratories And Healthcare Limited CIN - L33111MH2000PLC129883 Regd Office: SY No. 294/A H. No. 18, Swapnshilpa, Behind Aarti Apartment, Vartak Road, Virar (W), 401303 Tel No. +91 8975610000; E-Mail:cs@nidanhealthcare.co.in, Website: www.nidanhealthcare.co.in Statement of UnAudited Financial Results for the half year Ended as on 30th September 2025.</p>					
	Particulars	Half Year ended			Year Ended
		30-Sep-25	30-Sep-24	31-Mar-25	31-Mar-25
		Unaudited	Unaudited	Audited	Audited
1	Income				
	a) Revenue from Operations	1,312.10	1,053.27	1,399.48	2,452.75
	b) Other Income	116.96	103.09	121.97	225.06
	Total Income (a+b)	1,429.06	1,156.36	1,521.45	2,677.81
2	Expenses				
	a) Cost of Materials Consumed	40.35	47.99	54.16	102.15
	b) Changes in inventories of Finished Goods, Work in Progress and Stock-in-Trade	1.26	(0.79)	(23.73)	(24.52)
	c) Employee benefit expenses	211.77	183.82	267.74	451.56
	d) Finance Costs	88.48	87.93	126.45	214.38
	e) Depreciation and Amortization expenses	92.26	133.55	107.31	240.86
	f) Other Expenses	804.61	562.48	854.88	1,417.36
	Total Expenses (a to f)	1,238.74	1,014.99	1,386.81	2,401.79
3	Profit before Exceptional and Extraordinary Items & Tax	190.32	141.37	134.64	276.02
4	Exceptional & Extraordinary Items	-	-	-	-
5	Profit before Tax and after exceptional & extraordinary item (3-4)	190.32	141.37	134.64	276.02
6	Tax Expenses				
	a) Current Tax	43.50	36.00	29.00	65.00
	b) Deferred Tax Asset/Liability	3.45	(4.75)	9.82	5.07
	c) Tax of earlier year	-	-	8.26	8.26
	Total tax expenses	46.95	31.25	47.08	78.33
7	Profit for the period / year	143.37	110.13	87.56	197.69
8	Paid-up equity share capital (Face value of Rs 10/- per share) ended)	1,390	1,390	1,390	1,390
9	a) Basic EPS	1.03	0.79	0.63	1.42
	b) Diluted EPS	1.03	0.79	0.63	1.42

Notes:

1) The above Financial Results are reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on 10th November 2024.

2) The equity shares of the company are listed on SME Stock Exchange as referred in Chapter XB of SEBI (Issue of Capital and Disclosure requirements) Regulations, 2009 and hence exempted from Compulsary adoption of Ind AS for the preparation of Financial statements vide Notification dated 16th February, 2015 issued by ministry of corporate affairs.

3) The Company does not have different segments and hence segment wise reporting is not applicable to the Company.

4) The figures of the corresponding previous half year have been regrouped/rearranged wherever considered necessary to make them comparable

For and on behalf of Board of Directors
Nidan Laboratories and Healthcare Limited

(Signature)
Tejal Anil Jayakar
Executive Director & CFO
DIN:07984686



Date : 10th November 2025
Place : Mumbai


Nidan Laboratories And Healthcare Limited
Statement of Assets & Liabilities as at 30th September 2025

Rs in lakhs

	Particulars	As at 30th September 2025 (UnAudited)	As at 31st March 2025 (Audited)
I	Equity & Liabilities		
	1. Shareholders' funds		
	Equity Share Capital	1,390.00	1,390.00
	Reserves and Surplus	5,571.67	5,428.30
		6,961.67	6,818.30
	2. Non - Current Liabilities		
	(a) Long - Term Borrowings	377.11	389.51
	(b) Other Long term liabilities	7.39	7.39
	(c) Long Term Provisions	59.33	59.33
		443.83	456.23
	3. Current Liabilities		
	(a) Short - Term Borrowings	872.72	721.53
	(b) Trade Payables enterprises	7.73	30.78
	(ii) Total outstanding dues of creditors other than micro enterprises and small enterprises	53.75	65.49
	(c) Other Current Liabilities	133.93	142.72
	(d) Short - Term Provisions	101.88	59.05
		1,170.01	1,019.58
	TOTAL	8,575.51	8,294.11
II	Assets		
	1. Non - Current Assets		
	(a) Property Plant & Equipment and Intangible Assets		
	(i) Property, Plant & Equipments	1,548.91	1,631.94
	(ii) Intangible Asset	1.31	1.31
	(ii) Capital workin progress	15.11	15.11
	(b) Non-Current Investments	2,000.00	2,000.00
	(c) Long - Term Loans and Advances	3,463.55	3,379.76
	(d) Deferred Tax Asset (Net)	73.42	76.87
	(e) Other Non Current Assets	71.40	68.90
		7,173.70	7,173.89
	2. Current Assets		
	(a) Inventories	53.45	54.71
	(b) Trade Receivables	217.32	126.79
	(c) Cash and Cash Equivalents	179.84	189.94
	(d) Short - Term Loans and Advances	628.85	432.54
	(e) Other Current Assets	322.35	316.24
		1,401.81	1,120.22
	TOTAL	8,575.51	8,294.11

For and on behalf of Board of Directors
Nidan Laboratories and Healthcare Limited

Tejal Anil Jayakar
Executive Director & CFO
DIN:07984686



Date : 10th November 2025
Place : Mumbai

Nidan Laboratories And Healthcare Limited
Statement Of Cash Flows for the half year ended 30th September 2025

Particulars	Rs. in lakhs	
	Half Year ended 30th September 2025	Year ended 31st March 2025
<u>A - CASH FLOW FROM OPERATING ACTIVITIES</u>		
Profit Before Tax	190.32	276.02
Add/ (less) Adjustment for:		
Interest Income	(107.39)	(204.63)
Interest Expenses	85.11	180.91
Interest on income tax	-	25.71
Sundry Balance written off	-	-
Sundry balance written back	(3.96)	(16.83)
Depreciation on property plant & equipment	92.26	240.86
(Gain)/loss on disposal of property, plant and equipment	-	(3.16)
Operating Profit Before Working Capital Changes	256.34	498.88
Add/ (less): Adjustments for Changes in working capital:		
(Increase) / decrease in Trade Receivable	(90.53)	(74.35)
(Increase)/ decrease in Other Current Assets	(6.10)	(55.13)
(Increase) / decrease in Other Non current assets	(2.50)	0.91
(Increase) / decrease in Inventories	1.26	(24.52)
Increase / (decrease) in Trade payables	(30.84)	30.37
Increase / (decrease) in Long term liability	-	(9.25)
Increase / (decrease) in Other current Liability	(8.79)	15.42
Increase / (decrease) in Short Term Provision	(0.68)	2.55
Increase / (decrease) in Long term Provisions	-	2.85
Cash Generated from Operations	118.15	387.75
Add/ (less) : Direct taxes paid (net of refund received)	(0.01)	(160.08)
Net Cash Inflow / (outflow) from Operating Activities	118.15	227.66
<u>B - CASH FLOW FROM INVESTING ACTIVITIES</u>		
Acquisition of property, plant and equipment / intangible assets / Capital work in progress	(9.23)	(94.02)
Investment in group company	-	(2,000.00)
Proceeds from sale of property, plant and equipment	-	6.67
(Increase) / Decrease in Long term loans and advances (net)	(1.58)	12.85
(Increase) / decrease in Short Term Loans and Advances	(171.13)	1,982.79
Interest received	-	69.76
Net cash inflow/(outflow) from Investing Activities	(181.94)	(21.97)
<u>C - CASH FLOW FROM FINANCING ACTIVITIES</u>		
Proceeds / (repayment) of borrowings (net)	138.79	(119.83)
Interest Expenses	(85.11)	(180.91)
Net Cash inflow/(outflow) from Financing Activities	53.68	(300.73)
Net (Decrease) / Increase in Cash and Cash Equivalents (A+B+C)	(10.11)	(95.05)
Add: Cash and Cash Equivalents at the beginning of the year	189.95	284.99
Cash and Cash Equivalents at the end of the year	179.84	189.94


Cash and Cash Equivalents at the end of the year consists of cash in hand and Balances with Banks are as follows

Particulars	As at	
	30th September 2025	31st March 2025
Cash on hand	178.54	186.78
Balances with Banks	1.30	3.16
Cash and Cash Equivalents	179.84	189.94

For and on behalf of the Board of Directors
Nidan Laboratories And Healthcare Limited

(Signature)
Tejal Anil Jayakar
Executive Director & CFO
DIN: 07984686

Date : 10th November 2025
Place : Mumbai



Nidan Laboratories And Healthcare Limited**CIN - L33111MH2000PLC129883****Regd Office: SY No. 294/A H. No. 18, Swapnshilpa, Behind Aarti Apartment,
Vartak Road, Virar (w), 401303****Tel No. +91 8975610000, E-Mail : cs@nidanhealthcare.co.in, Website : www.nidanhealthcare.co.in****Statement of UnAudited Financial Results for the half year Ended on 30th September 2025**


S.No	Particulars	Half Year Ended 30th September 2025	Half Year Ended 30th September 2024	Half Year Ended 31st March 2025	Year Ended 31st March 2025
		(Unaudited)	(Unaudited)	(Audited)	(Audited)
1	Total Income from Operations	1,312.10	1,053.27	1,399.48	2,452.75
2	Net Profit for the period / year (before tax, exceptional and/or extraordinary items)	190.32	141.37	134.64	276.02
3	Net Profit for the period / year before tax (after exceptional and/or extraordinary items)	190.32	141.37	134.64	276.02
4	Net Profit for the period / year after tax (after exceptional and/or extraordinary items)	143.37	110.13	87.56	197.69
5	Total Comprehensive income for the period /year [comprising Profit for the period / year (after tax) and other comprehensive Income (after tax)]	143.37	110.13	87.56	197.69
6	Paid up Equity Share Capital	1,390.00	1,390.00	1,390.00	1,390.00
7	Reserves (exluding revaluation reserve)	5,571.67	5,340.73	87.56	5,428.30
8	Earnings Per Share (of Rs 10/-each) (not annualized)				
	Basic	1.03	0.79	0.63	1.42
	Diluted	1.03	0.79	0.63	1.42


1) The above is an extract of Audited Financial Results for half year ended 30th September 2025 which have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at the meeting held on 10th November 2025 and filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulation, 2015. The full format of the Financial Results are available on the Stock Exchange websites (www.nseindia.com/) and Company's website : www.nidanhealthcare.co.in

2) The Company does not have different segments and hence segment wise reporting is not applicable to the Company.

3) Figures of the previous period have been regrouped wherever necessary, to correspond with the figures of the current period.

**For and on behalf of Board of Directors
Nidan Laboratories and Healthcare Limited**


Tejal Anil Jayakar
Executive Director & CFO
DIN:07984686



Date : 10th November 2025

Place : Mumbai